Status:
COMPLETED
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
La Jolla Pharmaceutical Company
Conditions:
Shock, Surgical
Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. Currently, there is an a...
Eligibility Criteria
Inclusion
- Adult patients \> 18 years of age
- Receiving deceased donor kidney transplant
- Pre-transplant Ejection Fraction (within past 18 months) \> 50%
- Intraoperative or postoperative distributive shock (according to hospital and study protocol) requiring vasopressor support
Exclusion
- Pregnant patients (they would be excluded from receiving a transplant)
- Prisoners
- History of mesenteric ischemia
- History of aortic dissection
- History of abdominal aortic aneurysm
- Allergy to mannitol
- Absolute neutrophil count \< 1000 cell/mm3 (within past 18 months)
- Diagnosis of Raynaud's phenomenon, systemic sclerosis or vasospastic disease
Key Trial Info
Start Date :
August 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04529005
Start Date
August 13 2020
End Date
August 1 2021
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois Hospital and Health Sciences System
Chicago, Illinois, United States, 60612